These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 9633022

  • 1. Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.
    Funahashi H, Tanaka Y, Imai T, Wada M, Tsukamura K, Hayakawa Y, Matsuura N, Kikumori T, Oiwa M, Tominaga Y, Takagi H.
    J Endocrinol Invest; 1998 Jan; 21(1):43-7. PubMed ID: 9633022
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
    Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E.
    J Clin Invest; 1989 Sep; 84(3):728-32. PubMed ID: 2760211
    [Abstract] [Full Text] [Related]

  • 4. Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH)2D3.
    Finch JL, Brown AJ, Mori T, Nishii Y, Slatopolsky E.
    J Bone Miner Res; 1992 Jul; 7(7):835-9. PubMed ID: 1642151
    [Abstract] [Full Text] [Related]

  • 5. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ.
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism.
    Finch JL, Brown AJ, Kubodera N, Nishii Y, Slatopolsky E.
    Kidney Int; 1993 Mar; 43(3):561-6. PubMed ID: 8455354
    [Abstract] [Full Text] [Related]

  • 7. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
    Takahashi F, Furuichi T, Yorozu K, Kawata S, Kitamura H, Kubodera N, Slatopolsky E.
    Nephrol Dial Transplant; 2002 Mar; 17 Suppl 10():46-52. PubMed ID: 12386269
    [Abstract] [Full Text] [Related]

  • 8. The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands.
    Brown AJ, Zhong M, Finch J, Ritter C, Slatopolsky E.
    Endocrinology; 1995 Apr; 136(4):1419-25. PubMed ID: 7895652
    [Abstract] [Full Text] [Related]

  • 9. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
    Tsukamoto Y, Nomura M, Takahashi Y, Takagi Y, Yoshida A, Nagaoka T, Togashi K, Kikawada R, Marumo F.
    Nephron; 1991 Apr; 57(1):23-8. PubMed ID: 2046811
    [Abstract] [Full Text] [Related]

  • 10. On the mechanisms for the selective action of vitamin D analogs.
    Dusso AS, Negrea L, Gunawardhana S, Lopez-Hilker S, Finch J, Mori T, Nishii Y, Slatopolsky E, Brown AJ.
    Endocrinology; 1991 Apr; 128(4):1687-92. PubMed ID: 2004595
    [Abstract] [Full Text] [Related]

  • 11. In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency.
    Soliman E, Canaff L, Fox J, Hendy GN.
    Endocrinology; 1997 Jun; 138(6):2596-600. PubMed ID: 9165053
    [Abstract] [Full Text] [Related]

  • 12. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
    Nishii Y, Abe J, Mori T, Brown AJ, Dusso AS, Finch J, Lopez-Hilker S, Morrissey J, Slatopolsky E.
    Contrib Nephrol; 1991 Jun; 91():123-8. PubMed ID: 1800003
    [Abstract] [Full Text] [Related]

  • 13. 1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture.
    Cantley LK, Russell J, Lettieri D, Sherwood LM.
    Endocrinology; 1985 Nov; 117(5):2114-9. PubMed ID: 3840080
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
    Tamura S, Ueki K, Mashimo K, Tsukada Y, Naitoh M, Abe Y, Kawai H, Tsuchida A, Wakamatsu R, Nojima Y.
    Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
    [Abstract] [Full Text] [Related]

  • 15. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
    Monier-Faugere MC, Geng Z, Friedler RM, Qi Q, Kubodera N, Slatopolsky E, Malluche HH.
    Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
    [Abstract] [Full Text] [Related]

  • 16. Regulation of parathyroid hormone synthesis in chronic renal failure in rats.
    Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K.
    Kidney Int; 1991 May; 39(5):874-81. PubMed ID: 2067203
    [Abstract] [Full Text] [Related]

  • 17. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.
    Hirata M, Endo K, Katsumata K, Ichikawa F, Kubodera N, Fukagawa M.
    Nephrol Dial Transplant; 2002 May; 17 Suppl 10():41-5. PubMed ID: 12386268
    [Abstract] [Full Text] [Related]

  • 18. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus.
    Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, Kurokawa K.
    Nephron; 1995 May; 70(2):242-8. PubMed ID: 7566311
    [Abstract] [Full Text] [Related]

  • 19. Adaptation of parathyroid function to intravenous 1,25-dihydroxyvitamin D3 or partial parathyroidectomy in normal dogs.
    Cloutier M, Gagnon Y, Gascon-Barré M, Brossard JH, D'Amour P.
    J Endocrinol; 1997 Oct; 155(1):133-41. PubMed ID: 9390015
    [Abstract] [Full Text] [Related]

  • 20. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure.
    Denda M, Finch J, Slatopolsky E.
    Am J Kidney Dis; 1996 Oct; 28(4):596-602. PubMed ID: 8840952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.